Table 3.
Treatment approaches for unique patients with breast cancer entered into the COVID-19 Registry and Mastery Registry
| Tumor subtype | DCIS | Invasive cancer [total] | Invasive ER+/HER2− | Invasive ER any/HER2+ | Invasive triple-negative |
|---|---|---|---|---|---|
|
Primary surgery (usual) COVID-19 Registry only |
292 (60.3) | 996 (43.2) | 839 (48.5) | 58 (20.3) | 68 (29.7) |
|
Primary surgery (due to COVID) COVID-19 Registry only |
29 (6.0) | 47 (2.0) | 32 (1.8) | 7 (2.4) | 6 (2.6) |
| Neoadjuvant chemotherapy | |||||
| COVID-19 Registry (usual) | NA | 519 (22.5) | 156 (9.0) | 198 (69.2) | 150 (65.5) |
| Mastery Registry | NA | 1068 (21.1) | 142 (9.4) | 136 (57.4) | 127 (55.5) |
|
Neoadjuvant chemotherapy (due to COVID) COVID-19 Registry only |
NA | 61 (2.6) | 43 (2.5) | 10 (3.5) | 5 (2.2) |
| Neoadjuvant endocrine therapy | |||||
| COVID-19 Registry (usual) | 14 (2.9) | 124 (5.4) | 119 (6.9) | 4 (1.4) | 0 |
| Mastery Registry | 7 (3.0) | 286 (5.6) | 81 (5.4) | 1 (0.4) | 0 |
|
Neoadjuvant endocrine therapy (due to COVID) COVID-19 Registry only |
149 (30.8) | 560 (24.3) | 542 (31.3) | 9 (3.1) | 0 |
Data are expressed as n (%)
(Missing data from the Mastery Registry: 70% biomarker and 36% treatment approach)
COVID-19 coronavirus disease 2019, DCIS ductal carcinoma in situ, ER+ estrogen receptor-positive, HER2− human epidermal growth factor receptor-negative, HER2+ human epidermal growth factor receptor-positive